CoDAS
http://www.codas.periodikos.com.br/article/doi/10.1590/2317-1782/e20240298en
CoDAS
Artigo Original

Associations between quality of life in communication and sociodemographic and clinical aspects of Parkinson’s disease

Karoline de Abreu Silveira; Guilherme Briczinski de Souza; Camila Muratt Carpenedo; Carlos Roberto de Mello Rieder; Bárbara Costa Beber

Downloads: 0
Views: 21

Abstract

Purpose: To investigate the correlation between quality of life in communication among people with Parkinson’s disease and clinical and sociodemographic variables. Methods: Cross-sectional study that analyzed sociodemographic variables - such as sex, age, education and ethnicity - and clinical variables, including age at onset of symptoms, time since PD diagnosis, initial symptom, equivalent daily dose of levodopa, motor impairment, stage of the disease, cognition, mood disorders and quality of life. The correlation test and multiple linear regression model were used for statistical analysis. Results: The sample consisted of 34 individuals, with a mean age of 62.42 years (±12.21), mostly male (61.76%) and with a mean score of 20.09 (±17.78) in the communication item of the PDQ-39. A significant correlation was observed between communication and disease duration, depression and anxiety levels, activities of daily living, emotional well-being, stigma, social support, cognition, bodily discomfort, disease stage (Hoehn & Yahr), as well as motor and non-motor aspects and the total score of the PDQ-39 scale. This indicates that communication is affected by many areas of life and by the progression of the disease. When analyzed together (multiple linear regression model), activities of daily living and non-motor aspects (such as emotional and cognitive problems) are the main predictors of quality of life related to communication. Conclusion: Communication in individuals with PD is influenced by several factors related to the progression of the disease. Among them, activities of daily living and non-motor aspects stand out as the main influences on quality of life in communication.

Keywords

Parkinson Disease; Quality of Life; Communication; Signs and Symptoms; Speech Disorders

Referências

  • 1Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284-303. http://doi.org/10.1016/S0140-6736(21)00218-X PMid:33848468.
    » http://doi.org/10.1016/S0140-6736(21)00218-X
  • 2Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021;20(5):385-97. http://doi.org/10.1016/S1474-4422(21)00030-2 PMid:33894193.
    » http://doi.org/10.1016/S1474-4422(21)00030-2
  • 3Sapmaz Atalar MS, Oguz O, Genc G. Hypokinetic dysarthria in Parkinson’s disease: a narrative review. Medical Bulletin of Sisli Etfal Hospital. 2023;57(2):163-70. http://doi.org/10.14744/SEMB.2023.29560 PMid:37899809.
    » http://doi.org/10.14744/SEMB.2023.29560
  • 4Di Pietro DA, Olivares A, Comini L, Vezzadini G, Luisa A, Petrolati A, et al. Voice alterations, dysarthria, and respiratory derangements in patients with Parkinson’s disease. J Speech Lang Hear Res. 2022;65(10):3749-57. http://doi.org/10.1044/2022_JSLHR-21-00539 PMid:36194769.
    » http://doi.org/10.1044/2022_JSLHR-21-00539
  • 5Smith KM, Caplan DN. Communication impairment in Parkinson’s disease: impact of motor and cognitive symptoms on speech and language. Brain Lang. 2018;185:38-46. http://doi.org/10.1016/j.bandl.2018.08.002 PMid:30092448.
    » http://doi.org/10.1016/j.bandl.2018.08.002
  • 6Hall A. Quality of life and value assessment in health care. Health Care Anal. 2020;28(1):45-61. http://doi.org/10.1007/s10728-019-00382-w PMid:31338667.
    » http://doi.org/10.1007/s10728-019-00382-w
  • 7Crispino P, Gino M, Barbagelata E, Ciarambino T, Politi C, Ambrosino I, et al. Gender differences and quality of life in Parkinson’s disease. Int J Environ Res Public Health. 2020;18(1):198. http://doi.org/10.3390/ijerph18010198 PMid:33383855.
    » http://doi.org/10.3390/ijerph18010198
  • 8Zhao N, Yang Y, Zhang L, Zhang Q, Balbuena L, Ungvari GS, et al. Quality of life in Parkinson’s disease: a systematic review and meta‐analysis of comparative studies. CNS Neurosci Ther. 2021;27(3):270-9. http://doi.org/10.1111/cns.13549 PMid:33372386.
    » http://doi.org/10.1111/cns.13549
  • 9Bhanupriya R, Haridoss M, Lakshmi GS, Bagepally BS. Health-related quality of life in Parkinson’s disease: systematic review and meta-analysis of EuroQol (EQ-5D) utility scores. Qual Life Res. 2024;33(7):1781-93. http://doi.org/10.1007/s11136-024-03646-8 PMid:38581635.
    » http://doi.org/10.1007/s11136-024-03646-8
  • 10Tang Y, Liang X, Han L, Peng F, Shen B, Yu H, et al. Cognitive function and quality of life in Parkinson’s disease: a cross-sectional study. J Parkinsons Dis. 2020;10(3):1209-16. http://doi.org/10.3233/JPD-202097 PMid:32568115.
    » http://doi.org/10.3233/JPD-202097
  • 11Carroll V, Rossiter R, Blanchard D. Non-motor symptoms of Parkinson’s disease. Aust J Gen Pract. 2021;50(11):812-7. http://doi.org/10.31128/AJGP-07-21-6093 PMid:34713279.
    » http://doi.org/10.31128/AJGP-07-21-6093
  • 12Fan Y, Zhang M, Liang X, Shen B, Xu Z, Li S, et al. Determinants of quality of life in Parkinson’s disease: a perspective of novel clinical subtypes. Ann Clin Transl Neurol. 2021;8(11):2174-83. http://doi.org/10.1002/acn3.51475 PMid:34716746.
    » http://doi.org/10.1002/acn3.51475
  • 13Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-4. http://doi.org/10.1136/jnnp.55.3.181 PMid:1564476.
    » http://doi.org/10.1136/jnnp.55.3.181
  • 14Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649-53. http://doi.org/10.1002/mds.23429 PMid:21069833.
    » http://doi.org/10.1002/mds.23429
  • 15Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez‐Martin P, et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-70. http://doi.org/10.1002/mds.22340 PMid:19025984.
    » http://doi.org/10.1002/mds.22340
  • 16Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17(5):427-42. http://doi.org/10.1212/WNL.17.5.427 PMid:6067254.
    » http://doi.org/10.1212/WNL.17.5.427
  • 17Memória CM, Yassuda MS, Nakano EY, Forlenza OV. Brief screening for mild cognitive impairment: validation of the Brazilian version of the Montreal cognitive assessment. Int J Geriatr Psychiatry. 2013;28(1):34-40. http://doi.org/10.1002/gps.3787 PMid:22368034.
    » http://doi.org/10.1002/gps.3787
  • 18Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893-7. http://doi.org/10.1037/0022-006X.56.6.893 PMid:3204199.
    » http://doi.org/10.1037/0022-006X.56.6.893
  • 19Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561-71. http://doi.org/10.1001/archpsyc.1961.01710120031004 PMid:13688369.
    » http://doi.org/10.1001/archpsyc.1961.01710120031004
  • 20Carod‐Artal FJ, Martinez‐Martin P, Vargas AP. Independent validation of SCOPA–psychosocial and metric properties of the PDQ‐39 Brazilian version. Mov Disord. 2007;22(1):91-8. http://doi.org/10.1002/mds.21216 PMid:17094102.
    » http://doi.org/10.1002/mds.21216
  • 21Prell T, Schönenberg A, Heimrich KG. The impact of loneliness on quality of life in people with Parkinson’s disease: results from the survey of health, ageing and retirement in Europe. Front Med. 2023;10:1183289. http://doi.org/10.3389/fmed.2023.1183289 PMid:37425329.
    » http://doi.org/10.3389/fmed.2023.1183289
  • 22Vardanyan R, König HH, Hajek A. Association between Parkinson’s disease and psychosocial factors: results of the nationally representative german ageing survey. J Clin Med. 2022;11(15):4569. http://doi.org/10.3390/jcm11154569 PMid:35956184.
    » http://doi.org/10.3390/jcm11154569
  • 23Heimrich KG, Schönenberg A, Prell T. Social deprivation and exclusion in Parkinson’s disease: a cross-sectional and longitudinal study. BMJ Open. 2023;13(12):e074618. http://doi.org/10.1136/bmjopen-2023-074618 PMid:38159947.
    » http://doi.org/10.1136/bmjopen-2023-074618
  • 24Jaramillo-Jimenez A, Bocanegra Y, Buriticá O, Pineda Salazar DA, Moreno Gómez L, Tobón Quintero CA, et al. Subjective cognitive and communicative complaints and health-related quality of life in Parkinson’s disease with and without mild cognitive impairment. Rev Colomb Psiquiatr. 2023;52(4):305-13. http://doi.org/10.1016/j.rcp.2021.07.005 PMid:38065663.
    » http://doi.org/10.1016/j.rcp.2021.07.005
  • 25Ireland S, Carroll V, Blanchard D, Rossiter R. Recognising and responding to communication and swallowing difficulties in Parkinson’s disease. Aust J Gen Pract. 2022;51(4):239-44. http://doi.org/10.31128/AJGP-07-21-6094 PMid:35362009.
    » http://doi.org/10.31128/AJGP-07-21-6094
  • 26Hoseinipalangi Z, Kan FP, Hosseinifard H, Doustmehraban M, Masoumi M, Rafiei S, et al. Systematic review and meta-analysis of the quality-of-life of patients with Parkinson’s disease. East Mediterr Health J. 2023;29(1):63-70. http://doi.org/10.26719/emhj.23.013 PMid:36710616.
    » http://doi.org/10.26719/emhj.23.013
  • 27Galeoto G, Berardi A, Colalelli F, Pelosin E, Mezzarobba S, Avanzino L, et al. Correlation between Quality of Life and severity of Parkinson’s Disease by assessing an optimal cut-off point on the Parkinson’s Disease questionnaire (PDQ-39) as related to the Hoehn & Yahr (H&Y) scale. Clin Ter. 2022;173(3):243-8. PMid:35612339.
  • 28Prenger MT, Madray R, van Hedger K, Anello M, MacDonald PA. Social symptoms of Parkinson’s disease. Parkinsons Dis. 2020;2020(1):8846544. PMid:33489081.
  • 29Heimrich KG, Schönenberg A, Santos-García D, Mir P, Prell T, COPPADIS Study Group. The impact of nonmotor symptoms on health-related quality of life in Parkinson’s disease: a network analysis approach. J Clin Med. 2023;12(7):2573. http://doi.org/10.3390/jcm12072573 PMid:37048659.
    » http://doi.org/10.3390/jcm12072573
  • 30Kumar S, Goyal L, Singh S. Tremor and rigidity in patients with Parkinson’s disease: emphasis onepidemiology, pathophysiology and contributing factors. CNS Neurol Disord Drug Targets. 2022;21(7):596-609. http://doi.org/10.2174/1871527320666211006142100 PMid:34620070.
    » http://doi.org/10.2174/1871527320666211006142100
  • 31Dotov D, Cochen De Cock V, Driss V, Bardy B, Dalla Bella S. Coordination rigidity in the gait, posture, and speech of persons with Parkinson’s disease. J Mot Behav. 2023;55(4):394-409. http://doi.org/10.1080/00222895.2023.2217100 PMid:37257844.
    » http://doi.org/10.1080/00222895.2023.2217100
  • 32Rohl A, Gutierrez S, Johari K, Greenlee J, Tjaden K, Roberts A. Speech dysfunction, cognition, and Parkinson’s disease. Prog Brain Res. 2022;269(1):153-73. PMid:35248193.
  • 33Brown KA, Spencer KA. The relationship between speech characteristics and motor subtypes of Parkinson’s disease. Am J Speech Lang Pathol. 2020;29(4):2145-54. http://doi.org/10.1044/2020_AJSLP-20-00058 PMid:32997516.
    » http://doi.org/10.1044/2020_AJSLP-20-00058
  • 34Caballero-Eraso C, Carrera-Cueva C, Benito Zorrero E, Lopez-Ramirez C, Marin-Romero S, Asensio-Cruz MI, et al. Prospective study to evaluate quality of life in amyotrophic lateral sclerosis. Sci Rep. 2023;13(1):12074. http://doi.org/10.1038/s41598-023-39147-w PMid:37495641.
    » http://doi.org/10.1038/s41598-023-39147-w
  • 35Rosa Silva JP, Santiago JB Jr, Santos EL, Carvalho FO, França Costa IMP, Mendonça DMFD. Quality of life and functional independence in amyotrophic lateral sclerosis: a systematic review. Neurosci Biobehav Rev. 2020;111:1-11. http://doi.org/10.1016/j.neubiorev.2019.12.032 PMid:31917162.
    » http://doi.org/10.1016/j.neubiorev.2019.12.032
  • 36Gentili D, Deiana G, Chessa V, Calabretta A, Marras E, Solinas C, et al. Quality of life in amyotrophic lateral sclerosis patients and care burden of caregivers in Sardinia during COVID-19 pandemic. Healthcare. 2023;11(11):1641. http://doi.org/10.3390/healthcare11111641 PMid:37297781.
    » http://doi.org/10.3390/healthcare11111641
  • 37Manson A, Ciro C, Williams KN, Maliski SL. Identity and perceptions of quality of life in Alzheimer’s disease. Appl Nurs Res. 2020;52:151225. http://doi.org/10.1016/j.apnr.2019.151225 PMid:31899042.
    » http://doi.org/10.1016/j.apnr.2019.151225
  • 38Akpınar Söylemez B, Küçükgüçlü Ö, Akyol MA, Işık AT. Quality of life and factors affecting it in patients with Alzheimer’s disease: a cross-sectional study. Health Qual Life Outcomes. 2020;18(1):304. http://doi.org/10.1186/s12955-020-01554-2 PMid:32912233.
    » http://doi.org/10.1186/s12955-020-01554-2
  • 39Mank A, Rijnhart JJM, van Maurik IS, Jönsson L, Handels R, Bakker ED, et al. A longitudinal study on quality of life along the spectrum of Alzheimer’s disease. Alzheimers Res Ther. 2022;14(1):132. http://doi.org/10.1186/s13195-022-01075-8 PMid:36109800.
    » http://doi.org/10.1186/s13195-022-01075-8
  • 40Bolzan G, Leotti VB, Oliveira CM, Ecco G, Cappelli AH, Rocha AG, et al. Quality of life since pre-ataxic phases of Spinocerebellar Ataxia type 3/Machado–Joseph disease. Cerebellum. 2022;21(2):297-305. http://doi.org/10.1007/s12311-021-01299-8 PMid:34231179.
    » http://doi.org/10.1007/s12311-021-01299-8
  • 41Diaféria G, Bommarito S, Braga P No, Park SW, Padovani M, Haddad F, et al. Effect of speech therapy on quality of life in patients with spinocerebelar ataxia type 3. Arq Neuropsiquiatr. 2022;80(10):1017-25. http://doi.org/10.1055/s-0042-1755203 PMid:36535286.
    » http://doi.org/10.1055/s-0042-1755203

Submetido em:
22/09/2024

Aceito em:
10/05/2025

69011bc0a953955d6c5fe4a9 codas Articles

CoDAS

Share this page
Page Sections